FDA Drug Recalls

Recalls / Class II

Class IID-0085-2023

Product

Oxcarbazepine Tablets 600mg, packaged in a) 100- count bottles (NDC 62756-185-88), b) 500-count bottles (NDC 62756-185-13), c)1000-count bottles (NDC 62756-185-18), Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries Limited Halol-Baroda Highway, Halol-389 350, Gujarat, India.

Brand name
Oxcarbazepine
Generic name
Oxcarbazepine
Active ingredient
Oxcarbazepine
Route
Oral
NDCs
62756-183, 62756-184, 62756-185
FDA application
ANDA077794
Affected lot / code info
a) Lot HAC1474A, Expires 03/2023 b) Lot HAC1503A, Expires 03/2023 c) Lot HAC1474B, Expires 03/2023

Why it was recalled

Presence of foreign substance

Recalling firm

Firm
SUN PHARMACEUTICAL INDUSTRIES INC
Manufacturer
Sun Pharmaceutical Industries, Inc.
Type
Voluntary: Firm initiated
Address
2 Independence Way, Princeton, New Jersey 08540-6620

Distribution

Quantity
Lot HAC1474A: 4296 Bottles, Lot HAC1474B: 145 Bottles, Lot HAC1503A: 2124 Bottles
Distribution pattern
Nationwide within the United States

Timeline

Recall initiated
2022-12-01
FDA classified
2022-12-19
Posted by FDA
2022-12-28
Terminated
2023-09-13
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0085-2023. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Oxcarbazepine · FDA Drug Recalls